FOR TRANSLATIONAL RESEARCH IN NUCLEAR MEDICINE
Arronax Nantes brings together all stakeholders in Nantes working on research and development in nuclear medicine.
This more particularly include the laboratories of Arronax, Ceisam, CEMA-Oniris, CRCINA, the joint Nuclear Medicine department of the teaching hospital of Nantes and the ICO, LS2N, Subatech, and platforms originating from the ArronaxPlus equipment of excellence funded by the Future Investments Program (FIP).
Arronax Nantes is a stakeholder in the I-SITE NExT, in close collaboration with the laboratories of excellence IRON and IGO, the SIRIC ILIAD.
our publications
G.Blain, J.Vandenborre, A.Costagliola, F.Haddad, M.Fattahi, « La Radiolyse α Pulsée en radiochimie: De la radiolyse de l’eau vers de nombreuses applications en radiochimie », JECRRC, 01-07 Juin 2018, Strasbourg
Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT, Foubert F, Gouard S, Saï-Maurel C, Chérel M, Faivre-Chauvet A, Goldenberg DM, Barbet J, Bodet-Milin C, Bailly C, Carlier T, Kraeber-Bodéré F, Touchefeu Y, Frampas E. Oncotarget 2018, 9:27502-27513
our news
Opening of ISI NucMed registration
04/02/20
Kick-off for REPARE project
03/02/20
Astatine on the cover of the Physical Chemistry Chemical Physics journal
21/12/18
More than 120 participants in NTHS 2020
19/02/20
Just published – Cancers, vers une révolution thérapeutique?
10/12/19
A medical first in Nantes!
08/10/19Our equipments
en Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore.
Deserunt mollit “anim id est laborum, sed ut perspiciatis unde omnis” iste natus error sit voluptatem accusantium. doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae. (…)
